Lexaria Bioscience Reports $1.6 Million Net Loss, Sees Asset Growth Amid Strategic Shift

Lexaria Bioscience Corp. reported a net loss of $1.6 million for the three months ended November 30, 2025, a significant decrease from the $2.7 million loss recorded in the same period the previous year. The company did not generate any revenue during this quarter, a decline from $183,923 in the prior year, primarily due to the expiration of a licensing contract and a strategic shift away from B2B sales towards pharmaceutical applications. Operating expenses decreased to $1.57 million from $2.87 million year-over-year, driven by reduced research and development costs as the company nears completion of its Phase 1b clinical trial.

In terms of financial position, Lexaria's total assets increased to $6.05 million as of November 30, 2025, compared to $4.18 million at the end of August 2025. This growth was largely attributed to a rise in cash and cash equivalents, which reached approximately $4.3 million, up from $1.8 million. The company’s current liabilities also decreased slightly to $1.46 million from $1.49 million, resulting in a net working capital of $3.91 million, a notable improvement from $1.97 million in the previous quarter.

During the reporting period, Lexaria raised $3.4 million in net proceeds from a registered direct offering, which involved the issuance of 2,666,667 shares of common stock at $1.50 per share. The company also issued warrants to purchase additional shares, further enhancing its capital resources. However, despite these efforts, Lexaria acknowledged substantial doubt regarding its ability to continue as a going concern within the next twelve months, citing ongoing operational losses and the need for additional financing to support its business plans.

Operationally, Lexaria is advancing its research and development initiatives, particularly focusing on its DehydraTECH technology, which aims to enhance the bioavailability of active pharmaceutical ingredients. The company completed a significant clinical study in Australia, demonstrating positive safety and tolerability results for its formulations. Lexaria plans to continue exploring partnerships and licensing agreements to bolster its financial position and expand its product offerings in the pharmaceutical sector.

Looking ahead, Lexaria anticipates continued operational losses as it invests in R&D and clinical trials. The company is committed to optimizing its DehydraTECH formulations and exploring new therapeutic applications, particularly in the areas of diabetes and hypertension. However, the management has indicated that future financing will be crucial to sustain operations and achieve its strategic objectives.